HF
ALXO icon

HRT Financial’s ALX Oncology ALXO Stock Holding History

HRT Financial’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,535
Closed -$41K – 3119
2025
Q3 		$41K Buy
+22,535
New +$19.5K ﹤0.01% 2621
2024
Q2 		– Sell
-59,186
Closed -$659K – 2161
2024
Q1 		$659K Buy
+59,186
New +$831K ﹤0.01% 1109
2023
Q3 		– Sell
-25,176
Closed -$189K – 2350
2023
Q2 		$189K Sell
25,176
-57,369
-70% -$376K ﹤0.01% 1864
2023
Q1 		$373K Buy
+82,545
New +$625K ﹤0.01% 1580
2022
Q3 		– Sell
-86,470
Closed -$699K – 2737
2022
Q2 		$699K Buy
+86,470
New +$942K 0.01% 1252
2021
Q3 		– Sell
-6,590
Closed -$360K – 3235
2021
Q2 		$360K Buy
+6,590
New +$394K ﹤0.01% 2031

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HRT Financial's ALXO Position: Q4 2025 in Review

HRT Financial sold out of ALX Oncology (ALXO) in Q4 2025, closing a stake of 22,535 shares — an estimated $41K sold.

HRT Financial first reported a position in ALXO in Q2 2021 and held it in 6 quarters. The position peaked at $699K in Q2 2022. 57 funds tracked by Wall St. Rank hold ALXO as of Q4 2025.

  • HRT Financial reported no remaining ALX Oncology position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 22,535 ALX Oncology shares in Q4 2025, an estimated $41K.
  • HRT Financial first reported a position in ALX Oncology in Q2 2021 and held it in 6 quarters.
  • HRT Financial's ALX Oncology position peaked at $699K in Q2 2022.
  • 57 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.